Table 4. Comparative study of Indian publication on NSGCT.
| Study (year) | Number | Sites | Risk groups | Treatment | ORR | Toxicity | RPLND | EFS | OS |
|---|---|---|---|---|---|---|---|---|---|
| Raina et al [11] | 63 | Testis | NR | PBV + VAB-6: 100% | 81% | NR | NR | NR | 3 yr – 80% |
| Bhutani et al [8] | 53 | NR | Good – 41% Intermediate – 17% Poor – 40% |
NR | 92%a | Bleomycin lung injury – 1 (grade 5) FN – 4 (grade 5) |
12% | 2 yr – 57% | 2 yr – 70% |
| Singh et al [12] | 48 | Testis | Good risk – NR Intermediate risk – NR Poor risk – 40% |
NR | NR | NR | NR | NR | NR |
| Joshi et al [10] | 50 | Testis | Good – 9% Intermediate – 53% Poor – 38% |
BEP – 80% EP – 20% |
78% | FN – 22%, haematological – 53%, non-haemat – 13% | 40% | NR | NR |
| Saju et al [13] | 293 | Extra-cranial | Good – 32% Intermediate – 30% Poor – 38% |
BEP – 78% EP – 14% Carboplatin – 2% Others – 6% |
82% |
aFN – 13%, aBleomycin lung injury – 4 |
41% | 3 yr – 67.4% | 3 yr – 75.3% |
| Nair et al [14] | 119 | Testis | Good – 52% Intermediate – 28% Poor – 20% |
All BEP (except EP – 1 and VIP – 1) | 59% (CR) | FN – 12, bleomycin lung injury – 8 | N = 14 | 4 yr – 84.5% | 4 yr – 87.1% |
| Singh et al [9] | 19 | Testis |
aGood – 66% aIntermediate – 13% aPoor – 21% |
NR | 79%a | FN – 5.7%, Diarrhoea – 11% | NR | 3 yr – 69.2% | 3 yr – 71.4% |
| Current study (2020) | 100 | Testis, RP | Good – 46% Intermediate – 21% Poor – 33% |
BEP – 69% EP – 29% VIP – 2% |
90% | FN – 18%, bleomycin lung injury – 4 | 24% | 5 yr – 63.3% | 5 yr – 72.6% |
a
Combined seminoma and NSGCT
BEP, Bleomycin/etoposide/cisplatin; CR, Complete remission; EFS, Event free survival; EP, Etoposide/cisplatin; FN, Febrile neutropenia; ORR, Overall response rate; NR, Not reported; OS, Overall survival; PBV, Cisplatin/vinorelbine/bleomycin; RPLND, Retroperitoneal lymph node dissection; VAB-6, Cisplatin/vinblastine/actinomycin-D/bleomycin/cyclophosphamide; RP, retroperitoneum